When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EDIT - Down 35% This Year Is This Small-Cap Stock a Buy?
Editas Medicine Inc.
Gene-editing specialist Editas Medicine (NASDAQ: EDIT) has had a challenging 2022, even compared to the struggling stock market. The company's shares are down 35% this year and nearly 60% over the past 12 months. If the company can turn things around, its recent struggles merely represent an opportunity to get in on a discount.
Before pressing the buy button, however, let's consider whether Editas Medicine has what it takes to rebound from its woes.